This study found that Synchrodyn-17 peptide treatment in cancer patients undergoing chemotherapy reduced nausea, vomiting, and weakness. However, it also led to side effects like skin pigmentation, sodium retention, and hypertension.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: